The company and all members of the board guarantee that the information disclosed is true, accurate, and complete, with no false records, misleading statements, or significant omissions.
Special Reminder:
- According to the Company Law of the People's Republic of China and relevant regulations, shares held in the repurchase special account do not have the right to participate in profit distribution. Therefore, the 2025 annual equity distribution is based on the existing total share capital of 356,554,330 shares, excluding the 2,236,900 repurchased shares, resulting in a base of 354,317,430 shares.
- After the implementation of this equity distribution, the ex-dividend price will be calculated based on the total share capital of 356,554,330 shares (including repurchased shares). The cash dividend per 10 shares = total cash dividend / total share capital (including repurchased shares) * 10 = 53,147,614.50 yuan / 356,554,330 shares * 10 = 1.490589 yuan (retaining six decimal places, truncating the last digit without rounding). The reference price after the equity distribution will be the closing price on the last trading day before the ex-dividend date minus the cash dividend per share = closing price on the last trading day before the ex-dividend date - 0.1490589 yuan/share.
Hangzhou Minsheng Health Pharmaceutical Co., Ltd. (hereinafter referred to as "the Company") has had its 2025 annual profit distribution plan approved at the shareholders' meeting held on May 14, 2026. The details of the equity distribution are as follows: